HIMSHims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) | Price: $20.27 | Today's Change: -11.62%

What Happened

Hims & Hers Health filed two 8-K disclosures with the SEC on November 9, 2026, together covering its third-quarter FY2026 financial results (Item 2.02) and a change in company leadership (Item 5.02). For the quarter, the company reported revenue of $1.73 billion, operating income of $96.4 million, and net income of $49.5 million, with diluted earnings per share of $0.43. The simultaneous disclosure of an executive departure or appointment (Item 5.02) adds a layer of corporate governance news on top of the headline numbers.

Why It Matters

The financials reflect a company that has scaled to nearly $1.73 billion in quarterly revenue and returned to — or sustained — meaningful profitability, with a net income margin of roughly 2.9% on the quarter and positive operating income of $96.4 million. For investors, the dual filing raises an important near-term question: does the leadership change signal strategic continuity or a shift in direction at a moment when the company's growth trajectory and competitive positioning are under close scrutiny? The sharp single-day decline of more than 11% suggests the market is pricing in some uncertainty — whether around the executive transition, forward guidance not provided in the structured data, or both.

Analysis

On the surface, a quarter generating $1.73 billion in revenue with $49.5 million in net income is a material step for a telehealth and consumer health platform that has only recently demonstrated consistent profitability. The basic EPS of $0.48 and diluted EPS of $0.43 indicate a meaningful share count dilution factor worth monitoring, but both figures represent positive earnings momentum. The gap between operating income ($96.4 million) and net income ($49.5 million) suggests notable below-the-line charges — interest expense, tax items, or other costs — that investors should scrutinize in the full filing.

The executive change disclosed under Item 5.02 is the wildcard here. Without additional detail from the structured data, the nature and seniority of the transition remain to be parsed from the full 8-K text. Leadership changes at high-growth consumer health companies often catalyze re-rating events — either positive if a new operator signals operational discipline, or negative if the departure of a key figure raises execution risk.

The stock's sharp reaction — down over 11% on the day — is a signal worth watching. This follows StockWatch's existing initiating coverage on HIMS; readers should consult that report for the broader strategic context. Key things to monitor going forward include: the identity and mandate of the executive in question, any forward guidance embedded in earnings call commentary, and whether the revenue run-rate near $1.73 billion per quarter is sustainable as the competitive landscape in GLP-1 and telehealth shifts.

Disclaimer

This report is a news and informational summary based on publicly available SEC filings and structured financial data. It does not constitute investment advice, an offer to buy or sell securities, or an equity research recommendation. No rating or price target is issued or implied. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decision.

Existing Coverage

StockWatch has full coverage on HIMS, published 2026-09-22. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000242/hims-20261109.htm

Other filings for the same event:

• 8-K, 2026-11-09: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000245/hims-20261104.htm